|  |  |
| --- | --- |
| **Supplementary table 1. Clinical characteristics of patients with GBS** | |
| **Characteristics** | **N=49** |
| Neurologic symptoms on admission |  |
| Limb weakness | 49 (100) |
| Ascending paralysis | 25 (51) |
| Descending paralysis | 17 (35) |
| Non-defined (ascending or descending) paralysis | 7 (14) |
| Rapidly evolving quadriparesis\* | 5 (10) |
| Neuropathic pain | 23 (47) |
| Paresthesia | 23 (47) |
| Facial weakness | 2 (4) |
| Neurologic examination on admission | |
| Cranial neuropathy (Any) | 15 (31) |
| III, IV and VIa | 5 (10) |
| VII | 14 (29) |
| Unilateral | 3 (6) |
| Bilateral | 11 (22) |
| IX, X and XIIb | 8 (16) |
| Areflexia or hyporeflexia | 42 (86) |
| Sensory deficitc | 6 (12) |
| Ataxia | 1 (2) |
| Urinary sphincter involvement | 3 (6) |
| MRC sum score at admission | 42 (26-50) |
| Treatment | 47 (96) |
| IVIg onlyd | 25 (51) |
| 5 days (0.4mg/kg/d) | 17 (35) |
| 10 days (0.4mg/kg/d) | 7 (14) |
| Plasmapheresis only (all 5 sessions) | 9 (18) |
| Plasmapheresis and IVIG | 13 (27) |
| Outcomes | |
| Modified Rankin Scale at nadir | 4 (4 - 5) |
| Modified Rankin Scale at 6 months | 2 (1 - 2) |
| Modified Erasmus GBS Outcome Score | 5 (2 - 9) |
| Neuropathic Pain | 34 (69) |
| Mortality | 4 (8) |

Data are presented as n/N (%) or median (IQR).

\*Defined as weakness of four limbs in less than 24 hours

aOne patient had only VI nerve involvement.

bTwo patients did not have XII nerve involvement.

cSensory deficit is decrease or absent sensibility on physical exam.

dTreatment was withdrawn in one patient after 2 sessions of IVIG due to allergic reaction